Mark Lampert, Biotechnology Value Fund Up Stake In Cytokinetics, Inc. (CYTK), Reduce Exposure To Regado Biosciences Inc (RGDO)

Mark Lampert, the founder and manager of Biotechnology Value Fund, is bullish on Cytokinetics, Inc. (NASDAQ:CYTK). According to a recent filing with the Securities and Exchange Commission, Lampert has increased his fund’s stake from 1.79 million to 3.28 million shares, which include some 921,100 shares which can be issued upon the exercise of certain warrants. The fund’s current position accounts for 9.98% of the company’s common stock.

In another filing with the SEC, Biotechnology Value Fund has revealed a reduction in its holding of Regado Biosciences Inc (NASDAQ:RGDO) by 1.32 million shares that were disposed of, leaving the fund with 2.33 million shares which account for 9.99% of the company’s common stock.

Cytokinetics, Inc. (NASDAQ:CYTK)

Cytokinetics, Inc. (NASDAQ:CYTK) has also attracted the attention of Paul Ruddock and Steve Heinz, the managers of Lansdowne Partners. According to the fund’s latest 13F report, it holds 2.02 million shares valued at $13.1 million, the position suffering no changes in the previous quarter. Jim Simmons is also bullish on this stock, having initiated a position during the fourth quarter of 2013. Renaissance Technologies reported the ownership of 335,300 shares worth $2.17 million in its latest 13F filing. Israel Englander, the manager of Millennium Management, has decided to limit his exposure to Cytokinetics and has decreased his fund’s position by 36% to 554,700 shares valued at $3.6 million.

Cytokinetics, Inc. (NASDAQ:CYTK) engages in the research and design of small molecule therapeutics. The stock has a market cap of $326 million and does not pay a dividend. The stock has entered an uptrend at the end of 2013 and has advanced 38% so far this year to a current price of $8.95 per share. For the three months ending December 31, 2014, Cytokinetics posted revenues of $24.35 million and earnings per share of $0.22, up from a loss of $0.48 per share reported for the same period in 2012. Analysts expect the company to register $7.69 million in revenues and a loss per share of $0.35 during the current quarter.

Regado Biosciences Inc (NASDAQ:RGDO)

Only two hedge funds that we track have invested in Regado Biosciences Inc (NASDAQ:RGDO), one of them being Wexford Capital run by Charles Davidson. According to the fund’s latest 13F report, during the previous quarter, it has decreased its holding of the stock by 9% to 324,200 shares valued at $1.54 million. Alyeska Investment Group and its manager, Anand Parekh, are actually bullish and have increased their holding by 76% to 116,000 shares reportedly worth $553,000.

A developer of antithrombotic drug systems, Regado Biosciences Inc (NASDAQ:RGDO) has a market cap of $303 million and does not pay a dividend. The stock has been in an uptrend since the start of the year and has advanced 145% to a current price of $12 per share. For the year ending December 31, 2013, the company posted a net loss of $34.4 million, which translated into a loss per share of $4.59.

Disclosure: none.

Recommended reading:

CST Brands Inc (CST): Another Spin-Off Favored by Hedge Funds

Hedge Funds Go Crazy for Carter’s, Inc. (CRI)

Park West Asset Management Boosts Passive Stake In Move Inc. (MOVE)

Comments
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months. Our beta is only 1.2 (don't click this link if beating the market isn't important to you).

Lists

The 10 Largest Pharmaceutical Companies In the World

The 10 Most Expensive Android Apps

The 9 Most Expensive Designer Bags in the World

The 7 Most Expensive Real Estate in the World

The 10 Most Expensive eBay Items Ever Sold

The 10 Most Expensive iPhone Apps

The 9 Most Expensive Designer Shoes in the World

The 10 Most Expensive Cigarette Brands

The 10 Most Expensive Law Schools in the US

The 10 Best Wall Street Movies

The 10 Most Expensive Golf Clubs Ever Sold

The 10 Most Expensive Golf Memberships

The 10 Best Disney Characters Ever Created

The 8 Best Foods for Gaining Weight

The 10 Most Expensive Colleges in the World

The 7 Most Memorable Ad Campaigns of All Time

The 7 Most Expensive High Schools in the World

The 10 Electric Vehicles with the Longest Range

The 10 Cities with the Worst Drivers in the World

The 10 Most Expensive Dresses Ever Created

10 Islands to Visit Before You Die

10 Famous Celebrities Who Needed Rehab

The 15 Countries with the Largest Oil Reserves

The 10 Most Overused Excuses in the World

The 5 Best iOS Apps You Can’t Get on Android

5 Companies Damaged By Social Media Blunders

The 10 Most Legendary Blues Songs

The 10 Most Lawless Places in the World

4 Reasons China is a Threat to the US

The 17 Most Sugary Drinks in the World

The 10 Most Ruthless Rulers in History

The 10 Greatest Generals in History

Top 8 Travel Destinations for 2015

The 10 Safest Dog Breeds for Children

The 10 Most Stolen Vehicles in the US

The 7 Most Expensive Celebrity Weddings

The 10 Best LoL Teams in the World

Top 10 Worst Marketing Campaigns Ever Produced

Top 5 Diets that Help You Lose Weight

The 10 Best Ways to Stay Awake

7 Artists That Switched Musical Genres

The 10 Most Expensive Cities to Live in New Jersey

The 10 Best High Schools in New York

The 10 Countries With the Least Gender Inequality

The 6 Biggest Musician-Manager Feuds

The 10 Countries with the Cheapest Gas Prices

The 7 Most Theatrical Bands of All Time

The 8 Worst Band Breakups of All Time

The 10 Most Important South American Leaders

The 7 Most Successful Casting Show Winners

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!